Neurocritical Care News

PHILADELPHIA — An endovascular brain-computer interface allowed those who are paralyzed to perform computer-based activities, according to a presenter at the American Association of Neurological Surgeons annual meeting.

The FDA has granted fast track designation for Vaxxinity Inc.’s UB-311, an anti-amyloid beta immunotherapeutic vaccine, for the treatment of Alzheimer’s disease.

AstraZeneca has announced FDA approval of Ultomiris, a long-acting C5 complement inhibitor for the treatment of adults with generalized myasthenia gravis.

The FDA and European Commission have both granted orphan drug designation to AviadoBio for its new gene therapy to treat frontotemporal dementia, according to a company press release.

Ganaxolone was generally well tolerated and significantly reduced the frequency of seizures associated with CDKL5 deficiency disorder, according to a study published in The Lancet Neurology.

The FDA has granted breakthrough device designation to Quanterix Corp. for its Simoa neurofilament light chain plasma test, a prognostic aid that assesses risk for disease activity in patients with relapsing-remitting MS.

A collaboration between Mayo Clinic researchers and a team dedicated to researching frontotemporal dementia has identified neurofilament light as a useful biomarker for the disease.

Former college football players had a significantly higher prevalence of several health issues later in life than nonplayers, according to findings published in JAMA Network Open.

SEATTLE — COVID-19, caused by SARS-CoV-2 infection, is linked to a wide range of conditions that affect neurological processes, according to an expert at the 2022 American Academy of Neurology annual meeting.

SEATTLE — Although advancements have been made in immune checkpoint inhibitors, tumors such as glioblastoma present a roadblock to successful therapy, according to a presenter at the 2022 American Academy of Neurology annual meeting.